Semaglutide is designed for once-weekly dosing. Taking it every other week is not an approved schedule and may allow medication levels to fall enough for appetite control to weaken. If cost or side effects are driving the question, ask your provider about a lower weekly dose or another supervised plan instead of changing the interval yourself.
Written by Jen, BSN, RN, Clinical Aesthetics Injector. Medically reviewed by Josh Allen, D.O., Medical Director, InjectCo MedSpa.
Semaglutide typically follows a structured once-weekly schedule. Understanding why it is used this way, what happens when a dose is missed, and when adjustments may be appropriate can help you follow treatment safely without making unapproved changes.
Semaglutide belongs to a group of medications called GLP-1 receptor agonists. It acts on pathways involved in blood sugar regulation, slows stomach emptying, and may reduce appetite. These effects are why semaglutide may be prescribed as part of a medically supervised weight management plan.
The National Library of Medicine advises using semaglutide exactly as directed and not changing the amount or frequency without speaking with a healthcare provider.
Injectable semaglutide is designed for use on the same day each week. Its elimination half-life is approximately one week, which means medication remains in the body as the next scheduled dose approaches.
The current FDA prescribing information uses a once-weekly schedule. Extending that interval to two weeks allows a larger decline in medication levels and has not been established as a standard dosing plan.
Every-other-week dosing is not generally recommended during active weight loss. It is an off-label schedule that has not been established through the clinical trials used to support weekly treatment.
As medication levels fall, appetite control may become less consistent. The effect varies, but spacing doses without guidance may make it harder to assess whether treatment is working or causing side effects.
A missed dose is different from deliberately changing to an every-other-week schedule. Instructions vary by formulation and timing, so follow the directions supplied with your prescription or contact your provider.
Do not double a dose or create a new schedule on your own. If you have missed more than one dose, ask whether you need a different restart plan.
A provider may discuss a change when side effects, cost, treatment response, or maintenance goals make the current plan difficult to continue. The appropriate option may involve staying at the current dose longer, using a lower weekly dose, or considering another treatment.
Any change should be individualized. Changing your dose without your provider is not safe.
Cost is often the real reason. If the same supply lasts twice as long, taking semaglutide every other week can look like an obvious way to spend less.
The problem is that the apparent saving may come with less consistent medication exposure. If appetite control weakens before the next dose, the schedule may no longer support the outcome the patient is paying for.
A more appropriate question is whether a provider-supervised lower weekly dose could address the concern. Keeping the weekly interval may produce steadier exposure than taking a larger dose every two weeks. A lower dose may also use less medication, although the actual cost depends on the pharmacy, program, and insurance coverage.
The options are not interchangeable:
| Approach | What Changes | What to Know |
| Continue the prescribed weekly plan | Nothing | This follows the schedule used in clinical studies and prescribing information. |
| Discuss a lower weekly dose | The amount changes, but the weekly timing remains | This may be considered for tolerability, maintenance, or cost, depending on the provider’s assessment. |
| Take the usual dose every other week | The gap between doses doubles | Medication levels fluctuate more, and this is not an approved standard schedule. |
| Microdose | The amount is smaller than a standard prescribed dose | This is off-label, evidence is limited, and the dose should not be calculated without a provider. |
Insurance rules vary by plan, medical indication, and formulation. Ask the insurer what is covered and ask the clinic for the complete program cost before assuming that spacing doses will save money.
If your goal is to stop treatment, ask your provider how to taper off semaglutide safely. Review your semaglutide dosing plan first. There is no universal taper, and the right approach depends on your dose, response, side effects, and medical history.
Microdosing generally means using an amount smaller than a standard prescribed dose, sometimes below the approved starting dose. People may consider microdosing GLP-1 medication to manage side effects, reduce cost, or extend their supply. It is different from taking a regular dose every two weeks.
Microdosing semaglutide is off-label, and clinical evidence remains limited. It can also create dosing errors when patients try to convert milligrams into syringe units or work with different concentrations. The FDA has reported dosing errors involving compounded semaglutide products.
Before considering any change, a provider should review:
Microdosing is not a do-it-yourself strategy, and this article does not present it as an InjectCo protocol.
If cost or side effects are making weekly treatment difficult, review the concern with a licensed provider before changing the amount or schedule.
Maintenance is a different phase from active weight loss. A provider may begin that conversation after someone has reached a stable point, but there is no universal moment or single maintenance schedule that applies to everyone.
A semaglutide maintenance dose every other week is not an approved standard schedule. Some patients may discuss adjustments with a provider, but many plans continue weekly dosing. If a change is appropriate, a lower weekly dose may be considered before extending the interval.
A randomized maintenance trial found that continuing weekly semaglutide maintained its treatment effect better than stopping it. The study did not test every-other-week dosing, so it cannot establish that schedule as an equivalent maintenance option.
Maintenance planning should also account for how long people stay on semaglutide and the possibility of appetite or weight changes after treatment ends. InjectCo also explains practical steps for avoiding weight regain after stopping.
Individual results vary. Your provider should base any maintenance change on your response, health history, side effects, and ability to follow the plan consistently.
At InjectCo, our semaglutide program begins with a secure medical evaluation. A licensed provider reviews your health history and determines whether the program is clinically appropriate.
If compounded medication is prescribed, the program includes home delivery, injection guidance, and ongoing review. Compounded medications are not FDA-approved, and the provider should explain how that affects your treatment decision.
During follow-up, you can discuss cost, side effects, missed doses, or maintenance without adjusting the schedule on your own.
Review your current dose, side effects, budget, and long-term goals with an InjectCo provider before making a change.
Patients ask about semaglutide timing in several different ways, and each version of the question has a different answer. The ones below cover spacing doses further apart, what a provider may consider once someone reaches a maintenance stage, what happens when a week is missed, and what people mean by microdosing.
Semaglutide is designed for once-weekly use, and taking it every other week is not an approved standard schedule. Extending the interval allows medication levels to fall further, which may make appetite control and side effects less predictable. Only change your schedule if the provider managing your prescription recommends and monitors the adjustment.
Some providers may consider an individualized dosing change once a patient reaches the maintenance phase. However, every-other-week use remains off-label and has not been established as a standard maintenance regimen. Your provider may instead discuss continuing the current schedule, using a lower weekly dose, or considering another long-term strategy.
Semaglutide levels decline gradually because the medication has an elimination half-life of about one week. Skipping a dose may make appetite control, fullness, or blood sugar management less consistent, although the effect varies by person. Contact your provider for instructions, particularly if you have missed multiple doses or use semaglutide to manage diabetes.
Microdosing generally refers to taking an amount below a standard prescribed dose, but the term does not describe a single medically established protocol. It is different from taking a regular dose every other week because one changes the amount while the other changes the interval. Both approaches are off-label unless they match the instructions for your specific prescription.
There is not enough clinical evidence to describe semaglutide microdosing as a proven safe or effective strategy for weight management. Measuring or splitting doses incorrectly may lead to dosing errors, particularly when compounded products or unfamiliar concentration units are involved. Do not recalculate, split, or reduce your dose without instructions from the provider managing your treatment.
A lower weekly dose may provide more consistent medication exposure than taking a larger dose at longer intervals. However, the better option depends on why you want to adjust treatment, such as side effects, cost, weight maintenance, or inadequate response. Your provider should review these factors before recommending either approach.
Semaglutide has an elimination half-life of approximately one week and may remain in circulation for about five weeks after the final dose. The amount declines throughout that period, so its presence does not mean the full treatment effect remains constant for five weeks. Health conditions, dose, and treatment duration may also affect how the medication behaves in an individual patient.
Follow the missed-dose instructions supplied with your specific prescription because the recommended window varies by semaglutide product. If you are outside that window or have missed more than one dose, contact your provider before restarting. Do not double your next dose or create a new dosing schedule unless your provider specifically instructs you to do so.
Taking semaglutide less frequently may make a supply last longer, but it can also lead to less consistent medication exposure and appetite control. It may also make treatment response and side effects harder to evaluate. Ask your provider about the complete program cost, a supervised lower weekly dose, available savings options, or an alternative treatment that better fits your budget.
Maintenance may be considered when your weight, health markers, treatment response, and daily habits have reached a stage that can support a longer-term plan. Reaching a target weight does not automatically mean medication should be stopped or spaced farther apart. Your provider should review your side effects, medical needs, risk of weight regain, and long-term goals before defining the maintenance approach.
If cost, side effects, or maintenance are making weekly treatment difficult, bring that exact concern to the provider managing your prescription. The solution may involve a lower weekly dose or another supervised option, but it should not begin with experimenting on your own.
Individual results vary. Follow the instructions provided with your prescription and contact your provider before changing the dose or interval.
Talk with an InjectCo provider about cost, side effects, or maintenance before changing how often you take semaglutide.
This article is for general education and is not medical advice. It does not replace a consultation with a licensed provider. Individual results vary. Do not start, stop, or change any prescription medication without the provider managing your care.
Dr. Allen earned his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine and completed his emergency medicine residency with Texas A&M. As Medical Director, he reviews InjectCo’s treatments, protocols, and patient education content for accuracy and safety across all nine Texas locations.
